Free tool
FAERS Monitor: Injectafer
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203565 or its brand name (Injectafer, Ferric Carboxymaltose). Reports on generic versions are filed under their own applications.
Reports
4,728
Serious
2,512
53% of reports
Hospitalization
638
Death reported
90
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypophosphataemia871
- nausea553
- pain430
- dyspnoea399
- headache370
- product quality issue326
- dizziness310
- anxiety293
- urticaria288
- arthralgia280
- emotional distress259
- pruritus256
- anhedonia254
- blood phosphorus decreased233
- asthenia216
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 45 |
| 2015 | 170 |
| 2016 | 205 |
| 2017 | 395 |
| 2018 | 473 |
| 2019 | 656 |
| 2020 | 525 |
| 2021 | 578 |
| 2022 | 628 |
| 2023 | 352 |
| 2024 | 252 |
| 2025 | 257 |
| 2026 | 189 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,431 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypophosphataemiaSignal | 871 | 593.8 | 556.6 | 454,462 |
| blood phosphorus decreasedSignal | 233 | 302.8 | 266.0 | 65,349 |
| anhedoniaSignal | 254 | 43.4 | 38.5 | 10,392 |
| product quality issueSignal | 326 | 10.7 | 9.6 | 2,869 |
| emotional distressSignal | 259 | 9.5 | 8.5 | 1,977 |
| urticariaSignal | 288 | 7.7 | 6.8 | 1,671 |
| anxietySignal | 293 | 4.6 | 4.1 | 828 |
| dyspnoeaSignal | 399 | 3.1 | 2.9 | 594 |
| painSignal | 430 | 3.1 | 2.8 | 634 |
| nauseaSignal | 553 | 3.1 | 2.9 | 820 |
| arthralgiaSignal | 280 | 3.0 | 2.7 | 378 |
| pruritusSignal | 256 | 3.0 | 2.6 | 337 |
| dizzinessSignal | 310 | 2.8 | 2.5 | 356 |
| headacheSignal | 370 | 2.6 | 2.4 | 382 |
| astheniaSignal | 216 | 2.6 | 2.2 | 207 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.